Track market-moving stories before they get noisy

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

It also includes access to the Zacks Style Scores.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.8% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Cardinal Health (CAH - Free Report) Headquartered in Dublin, OH, Cardinal Health, Inc. is one of the world’s largest healthcare services and products providers, operating across Pharmaceutical and Specialty Solutions, Global Medical Products and Distribution (GMPD), and three Other growth businesses. The company serves nearly 90% of U.S. hospitals, delivers more than 43,000 pharmaceutical shipments daily, and manages a broad portfolio of medical, surgical, laboratory, and healthcare logistics offerings.

CAH is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 19.7; value investors should take notice.

Nine analysts revised their earnings estimate upwards in the last 60 days for fiscal 2027. The Zacks Consensus Estimate has increased $0.57 to $12.55 per share. CAH boasts an average earnings surprise of +14.7%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, CAH should be on investors' short list.

In the latest trading session, Cardinal Health (CAH - Free Report) closed at $240.49, marking a -2.71% move from the previous day. This move lagged the S&P 500's daily loss of 0.58%. On the other hand, the Dow registered a loss of 1.18%, and the technology-centric Nasdaq decreased by 0.32%.

The stock of prescription drug distributor has risen by 4.22% in the past month, leading the Medical sector's gain of 2.73% and the S&P 500's loss of 0.36%.

The investment community will be paying close attention to the earnings performance of Cardinal Health in its upcoming release. It is anticipated that the company will report an EPS of $2.92, marking a 14.51% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $66.96 billion, up 4.6% from the prior-year quarter.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $12.55 per share and a revenue of $266.02 billion, indicating changes of +11.46% and +4.63%, respectively, from the former year.

It is also important to note the recent changes to analyst estimates for Cardinal Health. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 4.23% higher. Cardinal Health presently features a Zacks Rank of #3 (Hold).

Digging into valuation, Cardinal Health currently has a Forward P/E ratio of 19.7. This indicates a premium in contrast to its industry's Forward P/E of 18.24.

One should further note that CAH currently holds a PEG ratio of 1.49. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Medical - Dental Supplies industry stood at 1.82 at the close of the market yesterday.

The Medical - Dental Supplies industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 75, placing it within the top 31% of over 250 industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.8% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Cardinal Health (CAH - Free Report) Headquartered in Dublin, OH, Cardinal Health, Inc. is one of the world’s largest healthcare services and products providers, operating across Pharmaceutical and Specialty Solutions, Global Medical Products and Distribution (GMPD), and three Other growth businesses. The company serves nearly 90% of U.S. hospitals, delivers more than 43,000 pharmaceutical shipments daily, and manages a broad portfolio of medical, surgical, laboratory, and healthcare logistics offerings.

CAH is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

Additionally, the company could be a top pick for growth investors. CAH has a Growth Style Score of A, forecasting year-over-year earnings growth of 11.5% for the current fiscal year.

For fiscal 2027, nine analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.57 to $12.55 per share. CAH boasts an average earnings surprise of +14.7%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, CAH should be on investors' short list.

Algert Global LLC grew its holdings in shares of Cardinal Health, Inc. (NYSE:CAH – Free Report) by 246.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 36,993 shares of the company’s stock after purchasing an additional 26,330 shares during the quarter. Algert Global LLC’s holdings in Cardinal Health were worth $8,788,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Integrated Wealth Concepts LLC raised its holdings in Cardinal Health by 6.9% in the first quarter. Integrated Wealth Concepts LLC now owns 4,363 shares of the company’s stock valued at $601,000 after buying an additional 280 shares during the period. Jones Financial Companies Lllp lifted its holdings in Cardinal Health by 198.3% in the 1st quarter. Jones Financial Companies Lllp now owns 21,112 shares of the company’s stock worth $27,000 after buying an additional 14,034 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in Cardinal Health in the 2nd quarter valued at about $1,935,000. Cerity Partners LLC grew its stake in shares of Cardinal Health by 17.0% during the second quarter. Cerity Partners LLC now owns 40,426 shares of the company’s stock valued at $6,792,000 after acquiring an additional 5,880 shares in the last quarter. Finally, Nebula Research & Development LLC grew its stake in shares of Cardinal Health by 34.4% during the second quarter. Nebula Research & Development LLC now owns 10,334 shares of the company’s stock valued at $1,736,000 after acquiring an additional 2,646 shares in the last quarter. Hedge funds and other institutional investors own 87.17% of the company’s stock.

Cardinal Health Stock Performance Shares of CAH stock opened at $238.61 on Thursday. The business’s fifty day moving average is $232.59 and its 200-day moving average is $218.25. The stock has a market cap of $55.50 billion, a PE ratio of 33.00, a price-to-earnings-growth ratio of 1.43 and a beta of 0.49. Cardinal Health, Inc. has a 1 year low of $145.87 and a 1 year high of $258.30.

Cardinal Health (NYSE:CAH – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported $2.91 EPS for the quarter, beating the consensus estimate of $2.42 by $0.49. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.53%. The business had revenue of $63.67 billion during the quarter, compared to analyst estimates of $65.15 billion. During the same period in the prior year, the business earned $2.08 earnings per share. The business’s quarterly revenue was up 5.8% on a year-over-year basis. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. Equities research analysts predict that Cardinal Health, Inc. will post 12.55 earnings per share for the current year. Cardinal Health Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be issued a dividend of $0.5158 per share. The ex-dividend date is Thursday, October 1st. This represents a $2.06 dividend on an annualized basis and a dividend yield of 0.9%. Cardinal Health’s payout ratio is currently 28.49%.

Insider Buying and Selling at Cardinal Health In related news, CEO Jason M. Hollar sold 80,000 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $235.74, for a total transaction of $18,859,200.00. Following the transaction, the chief executive officer directly owned 235,132 shares of the company’s stock, valued at approximately $55,430,017.68. The trade was a 25.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Stephen M. Mason sold 35,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $236.40, for a total transaction of $8,274,000.00. Following the sale, the chief executive officer owned 18,061 shares of the company’s stock, valued at approximately $4,269,620.40. This represents a 65.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 210,271 shares of company stock valued at $49,626,657 in the last ninety days. Company insiders own 0.12% of the company’s stock.

Wall Street Analyst Weigh In Several research analysts recently commented on CAH shares. Morgan Stanley boosted their price target on Cardinal Health from $255.00 to $265.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Bank of America increased their price objective on shares of Cardinal Health from $240.00 to $260.00 and gave the company a “buy” rating in a research note on Thursday, July 2nd. Weiss Ratings cut shares of Cardinal Health from a “buy (b+)” rating to a “buy (b)” rating in a report on Wednesday, August 19th. Zacks Research lowered shares of Cardinal Health from a “strong-buy” rating to a “hold” rating in a report on Friday, June 12th. Finally, Mizuho upped their target price on Cardinal Health from $240.00 to $250.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Sixteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, Cardinal Health has a consensus rating of “Moderate Buy” and an average price target of $266.56.

Check Out Our Latest Stock Analysis on CAH

Cardinal Health Profile (Free Report)

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.

Recommended Stories Five stocks we like better than Cardinal Health Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise Alcoa’s Gallium Project Opens a New Door Beyond Aluminum Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech Can Tesla’s Flying Roadster Distract From Its Real Risks?

Receive News & Ratings for Cardinal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardinal Health and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways Cardinal Health expects Pharma segment profit to grow 8-11%, supported by specialty and generic launches.Cell-and-gene therapy capabilities and non-core businesses are expanding CAH's growth opportunities.IRA pricing changes, GMPD execution challenges and $700 million in CapEx could pressure performance. Cardinal Health (CAH - Free Report) enters fiscal 2027 with strong momentum across pharmaceutical distribution, specialty solutions and growth businesses. Specialty pharmaceuticals, cell-and-gene therapy capabilities and expanding non-core operations should support earnings growth, while IRA-related pricing changes, GMPD execution challenges, tariffs and elevated operating costs could constrain its overall performance.

Shares of this Zacks Rank #3 (Hold) company have risen 11.7% so far this year compared with the industry's 5.2% growth and the S&P 500 Index’s 11.7% gain.

Cardinal Health, with a market capitalization of $53.38 billion, is a global specialty medical device company.

CAH’s bottom line is estimated to improve 14.9% over the next five years. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 14.72%.

Image Source: Zacks Investment Research

What's Driving CAH’s Performance?Pharma and Specialty Solutions Driving Robust Earnings Growth: Cardinal Health enters fiscal 2027 with strong momentum in its largest business, Pharmaceutical and Specialty Solutions. Revenues increased 6% to $58.8 billion in the fourth quarter of fiscal 2026, while segment profit rose 21% to $645 million, driven by brand and specialty portfolios and continued strength in generics.

Management expects Pharma revenues to grow 3-5% in fiscal 2027, with segment profit increasing 8-11%, supported by higher-margin Specialty growth, generic launches and distribution wins. Specialty revenues are expected to grow double digits, including new BioPharma Solutions customers, providing a favorable mix shift toward higher-margin businesses and reducing reliance on traditional pharmaceutical distribution.

Specialty and Cell-and-Gene Therapy Expand Addressable Market: Cardinal Health continues to build higher-value capabilities around specialty pharmaceuticals, particularly complex cell and gene therapies. Its 3PL business secured two additional gene-therapy commercialization agreements, bringing Cardinal Health's exclusive coverage to nearly half of the cell-and-gene market and approximately three-quarters of the total market. The newly opened Innovative Care Pharmacy further integrates specialty distribution, clinical support and financial solutions for high-cost therapies.

These investments should allow Cardinal to capture more economics across the pharmaceutical value chain as specialty drug utilization expands. The opportunity is particularly attractive because specialized services typically generate higher margins than traditional drug distribution.

Other Growth Businesses Provide Diversification: Cardinal's non-core growth businesses are increasingly becoming meaningful contributors to consolidated earnings. The group generated $1.7 billion in revenues during the fiscal fourth quarter, up 7%, while segment profit increased 14% to $183 million.

Management expects revenue growth of 11-13% and segment profit growth of 15-18% in fiscal 2027. Nuclear and Precision Health Solutions should benefit from strong Theranostics and PET demand, while OptiFreight continues to generate strong core volume growth. At-Home Solutions also has additional scale opportunities through Strive Medical and the planned AdaptHealth diabetes acquisition. This diversification should support faster profit growth than the core distribution business.

What’s Hurting CAH’s ProspectIRA Pricing Changes Will Continue to Constrain Growth: Cardina Health's Pharma business faces a recurring revenue headwind from changes associated with the Inflation Reduction Act (IRA). Management expects fiscal 2027 Pharma revenue growth of only 3-5%, partly because of the annualization of 2026 IRA price changes and implementation of 2027 changes. The company estimates that the 2027 impact on revenue growth will be generally consistent with the headwind experienced during the second half of fiscal 2026. Although management expects no adverse profit impact, lower reported revenue growth could limit the pace of top-line expansion. Uncertainty over whether these changes will ultimately be reflected in rebates or a lower WACC also complicates forecasting.

GMPD Remains a Low-Growth Business: Global Medical Products and Distribution continues to represent a structural challenge despite meaningful improvement. Cardinal Health expects GMPD revenues to increase only 2-4% in fiscal 2027, while segment profit is projected to be $200-$220 million, approximately $50 million above the fiscal 2026 figure, excluding the IEEPA refund.

The improvement depends on continued simplification, Cardinal Health brand growth and cost optimization. Management expects fiscal first-quarter GMPD profit to be roughly half of the prior-year level because of foreign currency and distributor purchase timing, with profit weighted toward the second half. This cadence creates execution risk and limits near-term earnings visibility.

Heavy CapEx Could Pressure Near-Term Cash Conversion: Cardinal Health's transformation increasingly depends on continued capital expenditure to support investment in infrastructure, automation, technology and acquisitions. The company expects $700 million in capital expenditures and $3.5-$4 billion in adjusted free cash flow in fiscal 2027, down from $5 billion in fiscal 2026. Recent acquisitions in At-Home Solutions, including Strive Medical and the planned AdaptHealth diabetes business, introduce integration and execution requirements even as management pursues additional tuck-in opportunities.

Although these investments are intended to generate future scale and synergies, they can constrain near-term cash conversion and increase complexity. The company must therefore balance investment in growth with its commitment to at least $1 billion in annual share repurchases.

Estimate TrendThe Zacks Consensus Estimate for fiscal 2027 revenues is pegged at $267.75 billion, implying growth of 5.3% from the year-ago reported figure. The consensus mark for adjusted EPS is pinned at $12.49, indicating an improvement of 10.9% from the previous year’s recorded level.

In the past 60 days, CAH’s earnings estimate for fiscal 2027 has improved 4%.

Stocks to ConsiderSome better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) andWest Pharmaceutical (WST - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

Callan Family Office LLC purchased a new stake in shares of Cardinal Health, Inc. (NYSE:CAH – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 11,365 shares of the company’s stock, valued at approximately $2,700,000.

A number of other large investors have also added to or reduced their stakes in the stock. Gambit Capital Management LLC purchased a new position in Cardinal Health in the second quarter valued at about $229,000. Laidlaw Wealth Management LLC bought a new position in shares of Cardinal Health during the 2nd quarter valued at approximately $609,000. C M Bidwell & Associates Ltd. purchased a new stake in shares of Cardinal Health during the 2nd quarter worth approximately $683,000. Keebeck Wealth Management bought a new stake in shares of Cardinal Health in the 2nd quarter worth approximately $348,000. Finally, Keating Financial Advisory Services Inc. bought a new stake in shares of Cardinal Health in the 2nd quarter worth approximately $56,000. Hedge funds and other institutional investors own 87.17% of the company’s stock.

Trending Headlines about Cardinal Health Here are the key news stories impacting Cardinal Health this week:

Positive Sentiment: Royal Bank of Canada initiated coverage with an “outperform” rating and a $276 price target, implying meaningful upside from recent trading levels. RBC cited Cardinal Health’s higher-margin services as a potential earnings-growth driver. RBC initiates coverage of Cardinal Health Positive Sentiment: Wall Street remains broadly constructive, with 16 analysts rating CAH a Buy and three assigning a Hold rating. The consensus rating is “Moderate Buy,” with an average price target of approximately $266.56. Zacks also identified Cardinal Health as a potentially attractive long-term value stock. Zacks value-stock analysis Positive Sentiment: Cardinal Health’s latest quarter delivered adjusted earnings per share of $2.91, well above the $2.42 consensus estimate, while revenue increased 5.8% year over year. Fiscal 2027 EPS guidance of $12.40–$12.60 supports the longer-term earnings case. Neutral Sentiment: The company declared a quarterly dividend of $0.5158 per share, equivalent to $2.06 annually and a yield of about 0.9%. The payout offers modest income support but is unlikely to be a major near-term catalyst. Negative Sentiment: Several executives sold sizable holdings around $235–$237 per share. CEO Jason Hollar sold 124,529 shares worth about $29.4 million, while other executive and insider sales—including those by Deborah Weitzman, Stephen Mason, Michelle Greene, Jessica Mayer and Mary Scherer—totaled roughly $20 million more. The concentrated selling and substantial reductions in insider ownership may encourage profit-taking concerns after CAH’s strong advance. Cardinal Health insider sales Negative Sentiment: Investors may also question the durability of the latest earnings beat because part of the improvement reportedly reflected a one-time tariff refund, potentially limiting the stock’s upside if recurring earnings growth does not match expectations. Cardinal Health earnings analysis Cardinal Health Trading Up 0.4% Shares of CAH stock opened at $229.48 on Friday. The firm’s 50 day moving average is $232.02 and its 200 day moving average is $217.86. The stock has a market capitalization of $53.37 billion, a P/E ratio of 31.74, a PEG ratio of 1.23 and a beta of 0.49. Cardinal Health, Inc. has a 12 month low of $145.87 and a 12 month high of $258.30. Cardinal Health (NYSE:CAH – Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.42 by $0.49. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.53%. The business had revenue of $63.67 billion during the quarter, compared to analyst estimates of $65.15 billion. During the same period in the previous year, the business earned $2.08 EPS. Cardinal Health’s revenue was up 5.8% compared to the same quarter last year. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. On average, equities analysts predict that Cardinal Health, Inc. will post 12.54 EPS for the current year.

Cardinal Health Dividend Announcement The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be given a $0.5158 dividend. The ex-dividend date is Thursday, October 1st. This represents a $2.06 annualized dividend and a dividend yield of 0.9%. Cardinal Health’s payout ratio is 28.49%.

Insider Buying and Selling In related news, CEO Jason M. Hollar sold 80,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $235.74, for a total transaction of $18,859,200.00. Following the sale, the chief executive officer directly owned 235,132 shares in the company, valued at approximately $55,430,017.68. The trade was a 25.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Stephen M. Mason sold 35,000 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $236.40, for a total value of $8,274,000.00. Following the sale, the chief executive officer directly owned 18,061 shares in the company, valued at $4,269,620.40. This trade represents a 65.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 210,271 shares of company stock valued at $49,626,657 in the last 90 days. Corporate insiders own 0.12% of the company’s stock.

Wall Street Analysts Forecast Growth Several brokerages have weighed in on CAH. Morgan Stanley increased their price objective on Cardinal Health from $255.00 to $265.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Bank of America boosted their target price on Cardinal Health from $240.00 to $260.00 and gave the company a “buy” rating in a research note on Thursday, July 2nd. Barclays upped their price target on Cardinal Health from $258.00 to $275.00 and gave the company an “overweight” rating in a research report on Thursday, August 13th. TD Cowen increased their price target on Cardinal Health from $275.00 to $280.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Finally, Evercore reissued an “outperform” rating and issued a $270.00 price objective on shares of Cardinal Health in a report on Wednesday, August 12th. Sixteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Cardinal Health has an average rating of “Moderate Buy” and a consensus price target of $266.56.

Read Our Latest Stock Report on CAH

Cardinal Health Profile (Free Report)

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.

Featured Articles Five stocks we like better than Cardinal Health 2 Biotech Stocks Shaping Up for Major Breakouts 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?

Receive News & Ratings for Cardinal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardinal Health and related companies with MarketBeat.com's FREE daily email newsletter.

Jessica L. Mayer, chief legal officer of Cardinal Health, Inc. (CAH +0.46%), sold 29,436 shares of common stock at $236.19 per share on August 18, according to an SEC Form 4 filing.

Transaction summaryMetricValueShares sold29,436Transaction value~$7.0 millionPost-transaction shares (directly held)33,076Post-transaction value$7.77 millionTransaction value based on SEC Form 4 weighted average sale price ($236.19); post-transaction value based on the August 18 market close ($234.98).

Key questionsWhat were the execution details of the transaction?
The shares were sold in multiple transactions at price intervals ranging from $234.07 to $237.67 per share.How does this move impact the insider's total ownership?
Following the disposition, Mayer direct ownership interest in the company is 0.01%.What is the current scale and valuation of the company?
Cardinal Health operates as a global healthcare services provider with a $55.0 billion market capitalization and trailing twelve-month revenue of $254.2 billion as of the August 19 market close.Company OverviewMetricValueShare Price (as of market close 2026-08-19)$234.85Market Capitalization$55.0 billionRevenue (TTM)$254.2 billionNet Income (TTM)$1.7 billionCompany SnapshotCardinal Health operates as a global, integrated healthcare services and products provider, delivering pharmaceutical distribution, medical supplies, and healthcare solutions across the United States, Canada, Europe, Asia, and international markets.The company generates revenue through its two core operating divisions--Pharmaceutical and Medical--which provide distribution, logistics, and specialized healthcare services to institutional and individual customers.Cardinal Health serves a diverse customer base, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical laboratories, physician practices, and patients receiving home-based care.Cardinal Health is one of the largest healthcare services and products companies globally. The company maintains a competitive position through its integrated distribution network, broad customer relationships, and diversified service offerings across pharmaceutical and medical segments. Cardinal Health's scale and operational infrastructure enable it to serve as a critical intermediary within the healthcare supply chain, supporting healthcare providers and patients across multiple geographies and care settings.

What this transaction means for investorsMayer wasn't alone on Aug. 18. CFO Aaron Alt sold 42,000 shares the same day, and CIO Michelle Greene sold 11,650, for example, and all three had performance share units settle on Aug. 15. Though the filing seems routine, Mayer's seat is what makes the filing worth reading. Analysts spent much of the Aug. 11 earnings call pressing management on 340B, the federal program requiring discounted drug prices for hospitals that serve low-income patients, plus Medicare price setting under the Inflation Reduction Act. CEO Jason Hollar was blunt about it, saying "we don't see our role changing and we don't believe our compensation should change."

Fiscal 2027 pharma revenue growth of 3% to 5% already builds in IRA pricing pressure, and Alt said the company is assuming the same percentage impact it just absorbed, roughly 500 basis points off segment revenue in the fourth quarter, offset almost exactly by GLP-1 volume. The January rate changes are the first live test of whether that offset holds.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Deborah Weitzman, CEO of the PSS Segment, reported a sale of 7,354 shares of Cardinal Health, Inc. (CAH +0.46%) in a recent SEC Form 4 filing.

Transaction summaryMetricValueTransaction value~$1.7 millionShares sold7,354Post-transaction shares (directly held)77,901Post-transaction value~$18.31 millionTransaction value based on SEC Form 4 weighted average sale price ($235.45); post-transaction value based on the August 18 market close ($234.98).

Key questionsHow does this liquidation impact the insider's equity position?
The sale of 7,354 shares reduced Weitzman's direct stake by 9%, leaving the executive with 77,901 direct shares valued at $18.31 million as of the August 18 transaction date close.What were the specific execution details of the trade?
The shares were disposed of at a weighted average price of $235.45, though individual execution prices ranged from $235.17 to $237.63 across multiple transactions.What is the broader financial context for Cardinal Health at the time of this filing?
As of the August 19 market close, shares were priced at $234.85, supporting a market capitalization of $55.0 billion for the Dublin-based firm, which reported trailing twelve-month revenue of $254.2 billion.Company OverviewMetricValueShare Price (as of market close 2026-08-19)$234.85Market Capitalization$55.0 billionRevenue (TTM)$254.2 billionNet Income (TTM)$1.7 billionCompany SnapshotCardinal Health operates as a global integrated provider of healthcare products and services, delivering pharmaceutical distribution, medical products, and healthcare services across the United States, Canada, Europe, Asia, and other international markets.The company generates revenue through its two core divisions--Pharmaceutical and Medical--which provide distribution, logistics, and value-added services to hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, and physician practices.Cardinal Health serves a diverse customer base, including healthcare providers, hospital systems, retail and specialty pharmacies, outpatient surgical centers, clinical laboratories, and physician practices, with additional reach into home healthcare and patient populations.Cardinal Health is one of the largest healthcare services and products companies globally, with a TTM revenue base of $254.2 billion and a market capitalization of $55.0 billion. The company maintains a competitive advantage through its integrated distribution network, scale across pharmaceutical and medical segments, and established relationships with a broad spectrum of healthcare providers across multiple geographies. With 58,788 employees worldwide, Cardinal Health is positioned as a critical infrastructure provider within the healthcare supply chain, supporting the delivery of care across institutional and individual patient settings.

What this transaction means for investorsWeitzman sold 7,354 shares and still finished August owning far more Cardinal stock than she did at the start of it. She held 52,877 shares before performance units landed on Aug. 4, and 77,901 once the dust settled, an increase of about 47%. The CEO, CFO, legal chief and CIO all came out of the same window roughly flat or down, so she's the one who took the award and mostly kept it.

Meanwhile, and importantly for long-term investors, Weitzman runs the segment that carried the quarter. Pharmaceutical and Specialty Solutions brought in $58.8 billion of revenue in the fourth quarter, up 6%, and segment profit rose 21% to $645 million. Specialty grew more than 25% across fiscal 2026. CEO Jason Hollar told analysts the company still sees "fantastic growth in our Biopharma Solutions business." For fiscal 2027, segment revenue is guided to 3% to 5% growth and profit to 8% to 11%, with 2 to 3 points of that profit coming from acquisitions already announced. CFO Aaron Alt said first-quarter profit growth should run near the top of the range before the Solaris deal laps in the second quarter, which is when the organic number gets its first clean look.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Aaron E. Alt, the chief financial officer of Cardinal Health, Inc. (CAH +0.46%), sold 42,000 shares of common stock on August 18, according to an SEC Form 4 filing.

Transaction summaryMetricValueTransaction value$9.9 millionShares sold42,000Post-transaction shares (directly held)20,495Post-transaction value$4.82 millionTransaction value based on SEC Form 4 weighted average sale price ($236.34); post-transaction value based on the August 18 market close ($234.98).

Key questionsWhat was the proportional impact of this sale on the insider's direct investment?
The disposal of 42,000 shares resulted in a reduction of the CFO's direct equity holdings, leaving a remaining balance of 20,495 shares.How did the execution price compare to the market's valuation on the transaction date?
The shares were sold at a weighted-average price of $236.34, slightly higher than the $234.98 market close on August 18.What is the current scale of the insider's remaining direct exposure?
The remaining 20,495 shares represent a total market value of $4.82 million based on the market close at the time of the transaction, while the company's broader insider ownership level is reported at 0.0088%.Company OverviewMetricValueShare Price (as of market close 2026-08-19)$234.85Market Capitalization$55.0 billionRevenue (TTM)$254.2 billionNet Income (TTM)$1.7 billionCompany SnapshotCardinal Health operates as a global, integrated healthcare services and products provider, delivering pharmaceutical distribution, medical supplies, and healthcare solutions across the United States, Canada, Europe, Asia, and international markets.The company generates revenue through its two core operating divisions--Pharmaceutical and Medical--which provide distribution, logistics, and specialized healthcare services to institutional and individual customers.Cardinal Health serves a diverse customer base, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical laboratories, physician practices, and patients receiving home-based care.Cardinal Health is one of the largest healthcare services and products companies globally, with TTM revenue of $254.2 billion. The company maintains a competitive position through its integrated distribution network, broad customer relationships, and diversified service offerings across pharmaceutical and medical segments. Cardinal Health's scale and operational infrastructure enable it to serve as a critical intermediary within the healthcare supply chain, supporting healthcare providers and patients across multiple geographies and care settings.

What this transaction means for investorsAlt held 26,408 shares before an Aug. 4 performance-unit award for Cardinal Health executives and then had 20,495 once the Aug. 18 selling was done, which brought in roughly $9.9 million and marked a slight reduction in the overall stake.

It's not unusual to see an executive manage their awards in such a way, and more important for long-term investors is what Alt ultimately heads up as CFO. Fourth-quarter EPS came in at $2.91, up 40%, but $0.31 of it was a one-time tariff refund, so Alt stripped it out and set the fiscal 2026 comparison at $10.95 rather than the $11.26 the company actually reported. Fiscal 2027 guidance of $12.40 to $12.60 is 13% to 15% growth against $10.95. Measured against $11.26, it's closer to 10% to 12%. "We did what we said we would do," Alt told analysts on the Aug. 11 call. Beyond those projections, he noted that the firm's plans and priorities remain unchanged, with planned capital expenditures of about $700 million, no significant actions needed to protect the firm's balance sheet, and at least $1 billion in share repurchases expected in the 2027 fiscal year.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

B. Metzler seel. Sohn & Co. AG acquired a new stake in Cardinal Health, Inc. (NYSE:CAH – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 26,592 shares of the company’s stock, valued at approximately $6,317,000.

Several other large investors have also added to or reduced their stakes in CAH. Kornitzer Capital Management Inc. KS increased its holdings in shares of Cardinal Health by 100.8% in the 4th quarter. Kornitzer Capital Management Inc. KS now owns 18,164 shares of the company’s stock worth $3,733,000 after buying an additional 9,120 shares during the last quarter. Abacus FCF Advisors LLC purchased a new position in shares of Cardinal Health in the 4th quarter worth about $7,182,000. Byrne Financial Freedom LLC bought a new position in shares of Cardinal Health during the 4th quarter valued at about $1,574,000. Belleair Asset Management LLC purchased a new position in shares of Cardinal Health in the fourth quarter worth about $1,100,000. Finally, Axecap Investments LLC bought a new position in shares of Cardinal Health in the fourth quarter worth approximately $2,371,000. Institutional investors own 87.17% of the company’s stock.

Analyst Ratings Changes CAH has been the subject of a number of recent analyst reports. Wells Fargo & Company upped their target price on Cardinal Health from $245.00 to $277.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th. William Blair began coverage on Cardinal Health in a report on Tuesday, April 28th. They issued an “outperform” rating on the stock. Evercore restated an “outperform” rating and set a $270.00 price objective on shares of Cardinal Health in a research note on Wednesday, August 12th. Bank of America lifted their target price on shares of Cardinal Health from $240.00 to $260.00 and gave the stock a “buy” rating in a report on Thursday, July 2nd. Finally, Royal Bank Of Canada assumed coverage on shares of Cardinal Health in a research report on Wednesday. They set an “outperform” rating and a $276.00 price target for the company. Sixteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Cardinal Health has a consensus rating of “Moderate Buy” and an average target price of $266.56.

Check Out Our Latest Research Report on Cardinal Health Insider Buying and Selling at Cardinal Health In other news, CEO Jason M. Hollar sold 44,529 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $236.18, for a total value of $10,516,859.22. Following the completion of the sale, the chief executive officer directly owned 190,603 shares of the company’s stock, valued at approximately $45,016,616.54. This represents a 18.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Deborah Weitzman sold 7,354 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $235.45, for a total transaction of $1,731,499.30. Following the completion of the transaction, the chief executive officer directly owned 77,901 shares in the company, valued at approximately $18,341,790.45. The trade was a 8.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 210,271 shares of company stock worth $49,626,657. 0.12% of the stock is owned by insiders.

Cardinal Health Trading Up 0.4% Shares of Cardinal Health stock opened at $229.48 on Friday. The firm has a market cap of $53.37 billion, a PE ratio of 31.74, a PEG ratio of 1.22 and a beta of 0.49. Cardinal Health, Inc. has a 12 month low of $145.87 and a 12 month high of $258.30. The stock has a 50 day moving average of $232.02 and a 200 day moving average of $217.86.

Cardinal Health (NYSE:CAH – Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $2.42 by $0.49. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.53%. The business had revenue of $63.67 billion for the quarter, compared to analyst estimates of $65.15 billion. During the same quarter in the prior year, the business earned $2.08 EPS. Cardinal Health’s quarterly revenue was up 5.8% on a year-over-year basis. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. As a group, equities research analysts forecast that Cardinal Health, Inc. will post 12.54 earnings per share for the current fiscal year.

Cardinal Health Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be paid a dividend of $0.5158 per share. The ex-dividend date is Thursday, October 1st. This represents a $2.06 annualized dividend and a dividend yield of 0.9%. Cardinal Health’s dividend payout ratio (DPR) is currently 28.49%.

Key Headlines Impacting Cardinal Health Here are the key news stories impacting Cardinal Health this week:

Positive Sentiment: Royal Bank of Canada initiated coverage with an “outperform” rating and a $276 price target, implying meaningful upside from recent trading levels. RBC cited Cardinal Health’s higher-margin services as a potential earnings-growth driver. RBC initiates coverage of Cardinal Health Positive Sentiment: Wall Street remains broadly constructive, with 16 analysts rating CAH a Buy and three assigning a Hold rating. The consensus rating is “Moderate Buy,” with an average price target of approximately $266.56. Zacks also identified Cardinal Health as a potentially attractive long-term value stock. Zacks value-stock analysis Positive Sentiment: Cardinal Health’s latest quarter delivered adjusted earnings per share of $2.91, well above the $2.42 consensus estimate, while revenue increased 5.8% year over year. Fiscal 2027 EPS guidance of $12.40–$12.60 supports the longer-term earnings case. Neutral Sentiment: The company declared a quarterly dividend of $0.5158 per share, equivalent to $2.06 annually and a yield of about 0.9%. The payout offers modest income support but is unlikely to be a major near-term catalyst. Negative Sentiment: Several executives sold sizable holdings around $235–$237 per share. CEO Jason Hollar sold 124,529 shares worth about $29.4 million, while other executive and insider sales—including those by Deborah Weitzman, Stephen Mason, Michelle Greene, Jessica Mayer and Mary Scherer—totaled roughly $20 million more. The concentrated selling and substantial reductions in insider ownership may encourage profit-taking concerns after CAH’s strong advance. Cardinal Health insider sales Negative Sentiment: Investors may also question the durability of the latest earnings beat because part of the improvement reportedly reflected a one-time tariff refund, potentially limiting the stock’s upside if recurring earnings growth does not match expectations. Cardinal Health earnings analysis Cardinal Health Company Profile (Free Report)

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.

Recommended Stories Five stocks we like better than Cardinal Health Blueprint for a Boom: SEC Clears the Crypto Runway Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss Advance Auto Parts Plunged, But Its Turnaround Is Still Working Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates? Want to see what other hedge funds are holding CAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardinal Health, Inc. (NYSE:CAH – Free Report).

Receive News & Ratings for Cardinal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardinal Health and related companies with MarketBeat.com's FREE daily email newsletter.

Advisors Capital Management LLC purchased a new stake in Cardinal Health, Inc. (NYSE: CAH) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 2,283 shares of the company's stock, valued at approximately $543,000. Several other institutional investors and hedge funds have also recently

Abacus FCF Advisors LLC acquired a new position in shares of Cardinal Health, Inc. (NYSE:CAH – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 20,694 shares of the company’s stock, valued at approximately $4,916,000.

A number of other large investors have also made changes to their positions in the stock. Investors Research Corp bought a new stake in shares of Cardinal Health in the 2nd quarter worth approximately $29,000. University of Texas Texas AM Investment Management Co. bought a new position in Cardinal Health in the fourth quarter worth $26,000. Allied Private Wealth LLC acquired a new stake in Cardinal Health during the second quarter worth $30,000. Bank of Jackson Hole Trust acquired a new stake in Cardinal Health during the fourth quarter worth $27,000. Finally, Indiana Trust & Investment Management Co acquired a new position in shares of Cardinal Health in the 1st quarter valued at $29,000. Institutional investors and hedge funds own 87.17% of the company’s stock.

Analyst Upgrades and Downgrades Several analysts have recently weighed in on CAH shares. Bank of America lifted their target price on shares of Cardinal Health from $240.00 to $260.00 and gave the company a “buy” rating in a research report on Thursday, July 2nd. Royal Bank Of Canada assumed coverage on Cardinal Health in a research note on Wednesday. They issued an “outperform” rating and a $276.00 target price for the company. Evercore reissued an “outperform” rating and issued a $270.00 price target on shares of Cardinal Health in a report on Wednesday, August 12th. Wells Fargo & Company boosted their price objective on shares of Cardinal Health from $245.00 to $277.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Finally, TD Cowen increased their price objective on Cardinal Health from $275.00 to $280.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. Sixteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Cardinal Health has a consensus rating of “Moderate Buy” and an average price target of $266.56.

Get Our Latest Analysis on CAH Cardinal Health Stock Down 0.1% CAH stock opened at $234.73 on Thursday. Cardinal Health, Inc. has a twelve month low of $145.87 and a twelve month high of $258.30. The company has a market cap of $54.59 billion, a P/E ratio of 32.47, a price-to-earnings-growth ratio of 1.26 and a beta of 0.49. The business’s fifty day moving average is $231.76 and its 200-day moving average is $217.68.

Cardinal Health (NYSE:CAH – Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported $2.91 EPS for the quarter, topping analysts’ consensus estimates of $2.42 by $0.49. Cardinal Health had a negative return on equity of 98.53% and a net margin of 0.67%.The business had revenue of $63.67 billion during the quarter, compared to analysts’ expectations of $65.15 billion. During the same period in the previous year, the firm earned $2.08 earnings per share. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. Research analysts anticipate that Cardinal Health, Inc. will post 12.54 earnings per share for the current fiscal year.

Cardinal Health Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Thursday, October 1st will be given a $0.5158 dividend. This represents a $2.06 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Thursday, October 1st. Cardinal Health’s dividend payout ratio (DPR) is currently 28.49%.

Cardinal Health Profile (Free Report)

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.

Featured Articles Five stocks we like better than Cardinal Health Bloom Energy’s AI Surge Meets a Valuation Reality Check Target Is Winning Shoppers Back—Can the Rally Reach $180? IonQ’s Space Contract Points to a New Frontier for Quantum Investors Is Apple’s AI Strategy Smarter Than Skeptics Think?

Receive News & Ratings for Cardinal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardinal Health and related companies with MarketBeat.com's FREE daily email newsletter.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Cardinal Health (CAH - Free Report) Headquartered in Dublin, OH, Cardinal Health is one of the world’s largest healthcare services and products providers, operating across Pharmaceutical & Specialty Solutions, Global Medical Products & Distribution (GMPD), and Other growth businesses. The company serves nearly 90% of U.S. hospitals, delivers more than 43,000 pharmaceutical shipments daily, and manages a broad portfolio of medical, surgical, and laboratory products.The Pharmaceutical and Specialty Solutions segment distributes a wide range of pharmaceutical products, including branded and generic drugs, specialty pharmaceuticals, and consumer health products. This segment also provides biopharma solutions, offering data-driven insights, analytics, and commercialization support to pharmaceutical manufacturers. CAH delivers specialty drug distribution services in areas such as oncology, gastroenterology, and rheumatology. Its pharmacy management services cater to hospital and retail pharmacies, enhancing medication access and supply chain efficiency. The company also operates nuclear pharmacies, compounding radiopharmaceuticals used in diagnostic imaging and treatment. It currently has nearly 130 nuclear pharmacies and 30 PET cyclotron facilities.

CAH is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

Additionally, the company could be a top pick for growth investors. CAH has a Growth Style Score of A, forecasting year-over-year earnings growth of 10.9% for the current fiscal year.

For fiscal 2027, eight analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.51 to $12.49 per share. CAH boasts an average earnings surprise of +14.7%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, CAH should be on investors' short list.

ABN AMRO Bank N.V. purchased a new stake in Cardinal Health, Inc. (NYSE: CAH) during the second quarter, according to its most recent filing with the SEC. The fund purchased 14,130 shares of the company's stock, valued at approximately $3,342,000. Several other hedge funds have also bought and sold shares of CAH. LWM

Cardinal Health delivered FY2026 non-GAAP EPS of $11.26, exceeding initial guidance and achieving over 30% growth, despite a slight revenue miss. CAH's profit mix is shifting toward higher-margin specialty and 'Other' businesses, making traditional distributor revenue metrics less relevant to earnings power. Management guides 13–15% EPS growth for FY2027, with my estimate at $13.10, implying 7–14% upside to a $258–$275 target range.

Key Takeaways CAH expects fiscal 2027 non-GAAP EPS of $12.40-$12.60, implying 13%-15% growth from its adjusted baseline.CAH guides pharma revenue growth of 3%-5% and profit growth of 8%-11%, assuming strong, not outsized demand.Board lifted buyback authorization by $5B to $6.4B; fiscal 2027 plans include at least $1B of repurchases. Cardinal Health, Inc. (CAH - Free Report) used its fourth-quarter fiscal 2026 call to focus on fiscal 2027 profit growth and normalized pharmaceutical demand. Management also emphasized scaling specialty businesses.

The company reported fourth-quarter non-GAAP EPS of $2.91, which topped the Zacks Consensus Estimate of $2.42. Revenues of $63.67 billion missed the $65.61 billion estimate. Meanwhile, management spent more time on the outlook.

CAH Sets Fiscal 2027 Growth Above Long-Term RangeCFO Aaron Alt said fiscal 2027 non-GAAP earnings are expected at $12.40-$12.60 per share. This represents 13%-15% growth from the adjusted $10.95 fiscal 2026 baseline, excluding the one-time tariff refund benefit.

Alt reconfirmed Cardinal Health's long-term EPS growth framework of 12%-14%. He said the fiscal 2027 range sits above that framework and includes a 19%-20% non-GAAP tax rate.

Alt expects adjusted free cash flow of $3.5-$4.0 billion. He also guided to about $700 million of capital expenditures and roughly 233 million weighted-average shares.

Cardinal Health Plans for Normalized Pharma DemandCFO Alt guided Pharmaceutical and Specialty Solutions revenue growth to 3%-5% and segment profit growth to 8%-11%. He said the plan assumes strong demand without the outsized demand seen in fiscal 2026.

A Morgan Stanley analyst asked whether Pharma momentum could continue. Alt said Specialty growth, generics performance and execution should carry forward, with completed M&A adding 2-3 percentage points to fiscal 2027 segment profit growth.

A UBS analyst asked about strong versus outsized demand. CEO Jason Hollar said Specialty growth should moderate from more than 25% in fiscal 2026 toward longer-term planning levels while remaining double-digit.

CAH Balances GMPD Recovery With Cost RisksCFO Alt expects Global Medical Products and Distribution revenue growth of 2%-4% and segment profit of $200-$220 million. He said the outlook excludes the fiscal 2026 IEEPA refund and assumes a modest tariff tailwind.

A TD Cowen analyst asked about input-cost pressure. CEO Hollar cited diesel fuel and petroleum-based commodities as pressures while emphasizing improved commercial protections and cost management.

Hollar said sustained cost pressure would move GMPD closer to the lower end of its profit range. He reiterated that the improvement plan remains focused on Cardinal Health brand growth, simplification and operational performance.

Cardinal Health Expands Specialty and At-HomeHollar described Specialty as an investment priority across distribution, Biopharma Solutions and multi-specialty MSOs. He said capacity additions remain tied to planned growth, including refrigeration and freezing capabilities.

Hollar highlighted two gene-therapy commercialization agreements and a new pharmacy for complex cell and gene therapies. He said those investments extend 3PL and specialty distribution capabilities.

Hollar said Advanced Diabetes Supply integration synergies are ahead of expectations. CFO  Alt added that Strive Medical and the announced AdaptHealth Diabetes Health acquisition should add 2 percentage points to fiscal 2027 Other profit growth.

CAH Expands Buyback Capacity and Keeps M&A OptionalAlt said fiscal 2027 plans include at least $1 billion of share repurchases. Hollar said the board increased repurchase authorization by $5 billion, bringing total authorization to $6.4 billion.

Alt said Cardinal Health is not assuming material M&A in fiscal 2027 guidance. He added that Cardinal Health retains flexibility for tuck-in deals, strategic M&A or additional capital returns.

Alt added fiscal 2026 repurchases totaled $1.35 billion at an average price of $187 per share. He pointed to investment in automation, technology and supply-chain capabilities.

Cardinal Health Keeps Execution at the CenterCEO Hollar framed fiscal 2027 around service levels, specialized-business growth and automation across distribution. He emphasized customer retention, operational reliability and capacity ahead of planned growth.

CFO Alt flagged uneven GMPD cadence, with segment profit weighted toward the second half. Together, Hollar and Alt framed fiscal 2027 around executing initiatives already underway rather than changing strategic direction.

CAH's Zacks Signals Favor Value and GrowthCAH carries a Zacks Rank #2 (Buy), with Value and Growth Scores of A, a Momentum Score of D and a VGM Score of A. Under the Zacks framework, a #1 (Strong Buy) or #2 Rank paired with A or B Style Scores is favorable, while the D Momentum Score tempers the timing signal. You can see the complete list of today’s Zacks #1 Rank stocks here.

The A-rated VGM Score combines value, growth and momentum characteristics into one measure. The Zacks Rank can change as earnings estimates are revised after the just-reported results, making the current signal dynamic rather than fixed.

Revenue: Total company revenue for Q4 fiscal 2026 was $63.7 billion, an increase of 6% year-over-year.Gross Profit: Gross profit grew 16% to $2.6 billion in the

Cardinal Health (CAH) shares are rising following a robust earnings report that surpassed expectations. The company has set its FY27 adjusted EPS guidance at $1

Key Takeaways Cardinal Health's fiscal Q4 adjusted EPS rose 40% to $2.91, beating estimates by 20.3%.CAH's Q4 revenues rose 6% to $63.67B, led by growth in Pharmaceutical and Specialty Solutions.Cardinal Health expects fiscal 2027 adjusted EPS of $12.40-$12.60, implying 13%-15% growth. Cardinal Health, Inc. (CAH - Free Report) reported fourth-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.91, beating the Zacks Consensus Estimate by 20.3%. The bottom line improved 40% year over year, aided by higher operating earnings, IEEPA tariff refunds, a lower tax rate and a reduced share count.

GAAP EPS in the quarter was $1.70 compared with $1.00 in the year-ago period.

Full-year fiscal 2026 adjusted EPS was $11.26, up 37% compared to the figure at the end of the fiscal 2025 period. The company reported GAAP EPS of $7.23 in fiscal 2026, compared with $6.45 in the year-ago period.

Q4 Revenue DetailsFor the fiscal fourth quarter, revenues were up 6% on a year-over-year basis to $63.67 billion. The top line, however, missed the Zacks Consensus Estimate by 2.9%.

For full-year fiscal 2026, CAH registered revenues of $254.25 billion, up 14% compared with fiscal 2025.

Shares of CAH were up 3.7% in pre-market trading. The company’s shares have climbed 15.4% in the year-to-date period compared with the industry’s 5.9% rise and the S&P 500 Index’s 13.1% gain.

Image Source: Zacks Investment Research

Segmental Analysis of CAHPharmaceutical and Specialty Solutions

Pharmaceutical and Specialty Solutions revenues increased 6% year over year to $58.85 billion. The improvement was driven by brand and specialty pharmaceutical sales growth from existing customers.

The segment’s profit totaled $645 million, up 21% from the year-ago period’s level. The upside was primarily driven by contributions from brand and specialty products and positive generics program performance.

Global Medical Products and Distribution

Revenues in this segment totaled $3.13 billion, down 2% year over year. The decline primarily reflected lower distribution volumes and the recognition of expected IEEPA tariff refund repayments to customers, partially offset by Cardinal Health brand growth.

The segment reported a profit of $150 million compared with $70 million in the year-ago quarter. This improvement was primarily driven by IEEPA tariff refunds.

Other

This segment includes three operating segments — Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight Logistics. Revenues totaled $1.72 billion, up 7% year over year, driven by growth across all three operating segments.

The segment’s profit amounted to $183 million, up 14% from the year-ago level. This upside was driven by growth in OptiFreight Logistics and at-Home Solutions.

Q4 Margin AnalysisGross profit increased 16% year over year to $2.56 billion. As a percentage of revenues, the gross margin in the reported quarter was approximately 4.0%, up almost 36 basis points year over year.

Distribution, selling, general and administrative expenses totaled $1.63 billion, up 10% year over year.

Operating income amounted to $729 million, up 70% year over year. Adjusted operating income increased 30% year over year to $935 million.

Financial UpdateThe company exited the reported quarter with cash and cash equivalents of $4.86 billion compared with $3.94 billion at the end of the third quarter of fiscal 2026.

Net cash provided by operating activities totaled $5.17 billion compared with $2.39 billion in the year-ago period.

CAH Sets FY27 Growth TargetsCardinal Health raised its fiscal 2027 earnings guidance.

CAH expects fiscal 2027 adjusted EPS in the range of $12.40-$12.60, implying growth of 13-15% from adjusted fiscal 2026 results excluding the IEEPA tariff refund benefit. The Zacks Consensus Estimate for the same is pegged at $12.04.

The company expects revenues from the Pharmaceutical and Specialty Solutions segment to grow 3-5% year over year. Segmental profit is projected to increase 8-11%.

Revenues from the Global Medical Products and Distribution segment are anticipated to grow 2-4%. Segmental profit is expected to be between $200 million and $220 million.

Revenues from the Other segment are likely to increase 11-13%. Segmental profit is projected to grow 15-18%.

Wrapping UpCardinal Health delivered mixed fourth-quarter fiscal 2026 results, with earnings surpassing estimates while revenues missed the same. Performance benefited from strength in Pharmaceutical and Specialty Solutions, while the company’s higher-margin growth businesses continued to expand across at-Home Solutions, Nuclear and Precision Health Solutions and OptiFreight Logistics.

Cardinal Health is strengthening these growth platforms through tuck-in acquisitions of Strive Medical and AdaptHealth’s Diabetes Health business. The company launched an outbound pharmacy shipping solution at OptiFreight Logistics and continues to invest in expanding PET and theranostics capabilities within Nuclear and Precision Health Solutions.

On the commercial front, CAH renewed its long-term wholesaler distribution contract with Kroger and plans to open a new Indianapolis distribution center in fiscal 2027 featuring advanced robotics and automation to increase capacity and operational flexibility.

Cardinal Health also remains focused on shareholder returns, completing $1.4 billion of share repurchases in fiscal 2026 and announcing an additional $5 billion repurchase authorization. Supported by continued investments in growth and a positive earnings outlook, the company is targeting sustained expansion across its core and higher-margin businesses.

CAH’s Zacks Rank & Other Key PicksCardinal Health carries a Zacks Rank #2 (Buy) at present.

Some other top-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted earnings per share (EPS) of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10.00%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.

COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.

For the quarter ended June 2026, Cardinal Health (CAH - Free Report) reported revenue of $63.67 billion, up 5.8% over the same period last year. EPS came in at $2.91, compared to $2.08 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $65.61 billion, representing a surprise of -2.96%. The company delivered an EPS surprise of +20.25%, with the consensus EPS estimate being $2.42.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Cardinal performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenue- Pharmaceutical and Specialty Solutions: $58.85 billion versus $60.99 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +6.3% change.Revenue- Other: $1.72 billion versus $1.8 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +7% change.Revenue- Global Medical Products and Distribution: $3.13 billion versus $3.26 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -2.2% change.Segment profit- Pharmaceutical and Specialty Solutions: $645 million compared to the $628.03 million average estimate based on two analysts.Segment profit- Other: $183 million versus $181.15 million estimated by two analysts on average.Segment profit- Global Medical Products and Distribution: $150 million versus the two-analyst average estimate of $42.02 million.View all Key Company Metrics for Cardinal here>>>

Shares of Cardinal have returned +1.5% over the past month versus the Zacks S&P 500 composite's +2.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

11.8.2026 15:58, CAH, JBL, APP

Index Dow Jones +0,42 % na 54204,36 b. S&P 500 0 % na 7753,01 b. Nasdaq Composite -0,34 % na 26515,59 b.

Nejsledovanější americké indexy se v úvodu úterního obchodování vyvíjejí smíšeně. V mírnějším tempu pokračuje výsledková sezóna, své výsledky hospodaření mimo jiné zveřejnily společnosti Hims & Hers Health (-4,0 %), On Holding (-21 %) a Sea Limited (+11,7 %). Podrobnosti naleznete v jednotlivých zprávách.

Daří se akciím společnosti Cardinal Health (+4,8 %), která se zabývá distribucí léčiv, zdravotnických a laboratorních potřeb a poskytováním služeb pro zdravotnictví, po zveřejnění výsledků za 4Q FY 2026. Společnost zaznamenala tržby ve výši 63,67 mld. USD, mírně pod odhady 65,16 mld. USD. Očištěný zisk na akcii ve výši 2,91 USD však překonal očekávání 2,42 USD. Trh se hlavně zaměřil na výhled očištěného zisku na akcii pro celý fiskální rok 2027, který společnost projektuje v rozmezí 12,40 až 12,60 USD, tedy nad očekáváním 12,06 USD.

V poklesu po výsledcích za 2Q pokračují akcie technologické společnosti AppLovin (-5,3 %), která provozuje reklamní platformu, přes kterou inzerenti oslovují uživatele mobilních aplikací. Analytici z Bank of America snížili doporučení z „Buy“ na „Neutral“ a zároveň snížili cílovou cenu ze 430 na 400 USD. Podle analytiků se zvýšila rizika spojená s deklarovaným dlouhodobým výhledem 30% meziročního růstu výnosů. Rizikovější jsou rovněž inovace, které mají dosažení tohoto 30% růstu podpořit. BofA nesnížila oceňovací násobek, protože se nedomnívá, že by AppLovin měl přijít o významný podíl na trhu. Podle analytiků je však nyní pravděpodobnější, že investoři začnou AppLovin vnímat jako vyspělou adtech platformu, pokud nepřijde nový inovační cyklus.

Analytici z UBS zvýšili doporučení pro společnost Jabil (+4,4 %), která se zabývá smluvní výrobou elektroniky, vývojem a designem produktů, z „Neutral“ na „Buy“, přičemž cílovou cenu ponechali beze změny na 430 USD. UBS očekává, že společnost čeká několikaletý růstový cyklus, který bude tažen investicemi do AI ze strany společností Amazon, Meta a Google, rostoucí poptávkou ve zdravotnictví s tím, jak budou uváděny do provozu nové kapacity, a také rozšiřováním trhů v oblasti automatizace a robotiky. Podle analytiků by tyto faktory měly podpořit růst tržeb Jabilu a ve fiskálním roce 2027 zvýšit provozní marži nad 6 %.

Intel (-0,8 %) navyšuje veřejnou nabídku akcií na 20 mld. USD, cena byla stanovena na 95 USD za akcii.

Index S&P 500 0 % na 7753,01 b. Nejsilnější sektory S&P Změna Nejslabší sektory S&P Změna Průmysl +1,1 % Komunikační služby -1,1 % Utility +0,8 % Zbytná spotřeba -0,5 % Zdravotní péče +0,6 % Reality -0,2 % Nejsilnější akcie S&P Změna Nejslabší akcie S&P Změna Cardinal Health (CAH) +4,8 % Carvana (CVNA) -5,9 % Jabil (JBL) +4,4 % AppLovin Corp (APP) -5,3 % KKR (KKR) +4,2 % Ventas (VTR) -4,0 % Ares Management Corp (ARES) +3,9 % Datadog (DDOG) -3,9 % Teradyne (TER) +3,7 % Oracle Corp (ORCL) -3,9 % Zdroj: Bloomberg

Michal Bárta
Fio banka, a.s.
Prohlášení

Cardinal Health reports mixed quarterly performance across its business segments as earnings get a lift from one-time tariff refunds.

Cardinal Health (CAH - Free Report) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.42 per share. This compares to earnings of $2.08 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +20.25%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $2.8 per share when it actually produced earnings of $3.17, delivering a surprise of +13.21%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Cardinal, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $63.67 billion for the quarter ended June 2026, missing the Zacks Consensus Estimate by 2.96%. This compares to year-ago revenues of $60.16 billion. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Cardinal shares have added about 15.4% since the beginning of the year versus the S&P 500's gain of 13.3%.

What's Next for Cardinal?While Cardinal has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Cardinal was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $2.86 on $69.77 billion in revenues for the coming quarter and $12.04 on $278.73 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 14% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, The Cooper Companies (COO - Free Report) , has yet to report results for the quarter ended July 2026. The results are expected to be released on September 9.

This surgical and contact lens products maker is expected to post quarterly earnings of $1.11 per share in its upcoming report, which represents a year-over-year change of +0.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

The Cooper Companies' revenues are expected to be $1.1 billion, up 3.8% from the year-ago quarter.

Fourth quarter revenue increased 6% to $63.7 billion Fourth quarter GAAP1 diluted EPS increased 70% to $1.70 Excluding a one-time positive impact of $0.31 from the recognition of the IEEPA tariff refund, fourth quarter non-GAAP diluted EPS increased 25% to $2.60, with reported fourth quarter non-GAAP diluted EPS increasing 40% to $2.91 For fiscal year 2026, excluding the IEEPA tariff refund recognition, non-GAAP diluted EPS increased 33% to $10.95, with reported non-GAAP diluted EPS increasing 37% to $11.26 Fiscal year 2026 operating cash flow $5.2 billion and adjusted free cash flow $5.0 billion Incremental $350 million share repurchase completed, bringing fiscal year 2026 repurchase total to $1.4 billion, with $5.0 billion incremental repurchase authorization approved by board of directors Cardinal Health provides fiscal year 2027 non-GAAP EPS guidance2 of 13% to 15% growth3 ($12.40 to $12.60), above the Company's long-term EPS guidance , /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported fourth quarter fiscal year 2026 revenues of $63.7 billion, an increase of 6% from the fourth quarter of fiscal year 2025. Fourth quarter GAAP operating earnings increased 70% to $729 million and GAAP diluted earnings per share (EPS) increased 70% to $1.70.

Fourth quarter non-GAAP operating earnings increased 30% to $935 million. Non-GAAP diluted EPS increased 40% to $2.91, reflecting the increase in non-GAAP earnings, including the recognition of a one-time net operating profit impact of IEEPA tariff refunds of $100 million in the GMPD segment, a lower non-GAAP effective tax rate, and a lower share count, partially offset by an increase in interest and other expense.

Fiscal year 2026 revenues were $254.2 billion, a 14% increase from fiscal year 2025. GAAP operating earnings were $2.6 billion and GAAP diluted EPS was $7.23. Non-GAAP operating earnings increased 30% to $3.6 billion, driven by segment profit increases across all five operating segments. Non-GAAP diluted EPS increased 37% to $11.26 for the year, reflecting the increase in non-GAAP operating earnings across the business, including the recognition of a one-time net operating profit impact of IEEPA tariff refunds of $100 million in the GMPD segment, a lower non-GAAP effective tax rate, and a lower share count following in-year share repurchases, partially offset by an increase in interest and other expense.

"Fiscal 2026 was a standout year for Cardinal Health and I am pleased with our strong fourth quarter results," said Jason Hollar, CEO of Cardinal Health. "The broad-based operational strength for the year, with all five of our operating segments growing profit double-digits, even before recognition of IEEPA tariff recoveries in GMPD, reflects the disciplined execution of our strategy and our investments for growth. We enter Fiscal 2027 with momentum and confidence in our ability to deliver continued shareholder value creation."

Q4 and full year FY26 summary

Q4 FY26

Q4 FY25

Y/Y

FY26

FY25

Y/Y

Revenue

$63.7 billion

$60.2 billion

6 %

$254.2 billion

$222.6 billion

14 %

Operating earnings

$729 million

$428 million

70 %

$2.6 billion

$2.3 billion

15 %

Non-GAAP operating earnings

$935 million

$719 million

30 %

$3.6 billion

$2.8 billion

30 %

Net earnings attributable to Cardinal Health, Inc.

$398 million

$239 million

67 %

$1.7 billion

$1.6 billion

10 %

Non-GAAP net earnings attributable to Cardinal Health, Inc.

$682 million

$501 million

36 %

$2.7 billion

$2.0 billion

34 %

Effective Tax Rate

27.9 %

36.9 %

21.6 %

25.3 %

Non-GAAP Effective Tax Rate

22.5 %

26.3 %

19.0 %

23.3 %

Diluted EPS attributable to Cardinal Health, Inc.

$1.70

$1.00

70 %

$7.23

$6.45

12 %

Non-GAAP diluted EPS attributable to Cardinal Health, Inc.

$2.91

$2.08

40 %

$11.26

$8.24

37 %

Segment results

Pharmaceutical and Specialty Solutions segment

Q4 FY26

Q4 FY25

Y/Y

FY26

FY25

Y/Y

Revenue

$58.8 billion

$55.4 billion

6 %

$234.8 billion

$204.6 billion

15 %

Segment profit

$645 million

$535 million

21 %

$2.8 billion

$2.3 billion

23 %

Fourth quarter revenue for the Pharmaceutical and Specialty Solutions segment increased 6% to $58.8 billion, driven by brand and specialty pharmaceutical sales growth from existing customers.

Pharmaceutical and Specialty Solutions segment profit increased 21% to $645 million in the fourth quarter, primarily driven by contributions from brand and specialty products and positive generics program performance.

Global Medical Products and Distribution segment

Q4 FY26

Q4 FY25

Y/Y

FY26

FY25

Y/Y

Revenue

$3.1 billion

$3.2 billion

(2) %

$12.7 billion

$12.6 billion

1 %

Segment profit

$150 million

$70 million

N.M.

$258 million

$135 million

91 %

Fourth quarter revenue for the Global Medical Products and Distribution segment decreased 2% from the prior year to $3.1 billion. This decrease was primarily driven by lower distribution volumes and the recognition of the expected IEEPA tariff refund repayment to customers, partially offset by Cardinal Health brand growth.

Global Medical Products and Distribution segment profit increased to $150 million in the fourth quarter, primarily driven by IEEPA tariff refunds.

Other4

Q4 FY26

Q4 FY25

Y/Y

FY26

FY25

Y/Y

Revenue

$1.7 billion

$1.6 billion

7 %

$6.8 billion

$5.4 billion

26 %

Segment profit

$183 million

$160 million

14 %

$707 million

$516 million

37 %

Fourth quarter revenue for Other increased 7% to $1.7 billion, driven by growth across the three operating segments: Nuclear and Precision Health Solutions, OptiFreight Logistics, and at-Home Solutions.

Other segment profit increased 14% to $183 million in the fourth quarter, driven by growth in OptiFreight Logistics and at-Home Solutions.

Fiscal year 2027 outlook2

The company released its fiscal year 2027 outlook for non-GAAP diluted EPS of +13% to +15% growth3 ($12.40 to $12.60).

Non-GAAP earnings per share

$12.40 to $12.60

Pharmaceutical and Specialty Solutions segment:

Revenue

3% to 5% growth

Segment profit

8% to 11% growth

Global Medical Products and Distribution segment:

  Revenue

2% to 4% growth

Segment profit

$200 million to $220 million

Other (NPHS, at-Home Solutions, OptiFreight Logistics):

  Revenue

11% to 13% growth

Segment profit

15% to 18% growth

Interest and other

$240 million to $290 million

Non-GAAP effective tax rate

19.0% to 20.0%

Diluted weighted average shares outstanding

~233 million

Share repurchases

~$1 billion

Capital Expenditures

~$700 million

Non-GAAP adjusted free cash flow

$3.5 billion to $4.0 billion

Financial guidance for fiscal year 2027 reflects the estimated impact of the Company's recently completed tuck-in acquisition of Strive Medical and the announced tuck-in acquisition of the Diabetes Health business of AdaptHealth.

Recent highlights

Cardinal Health recently completed an additional $350 million accelerated share repurchase program, bringing year-to-date share repurchases in fiscal year 2026 to $1.4 billion. Cardinal Health Board of Directors approved a $5.0 billion increase to the share repurchase program, bringing the total share repurchase authorization to $6.4 billion as of August 2026 Cardinal Health announces simplification of credit facilities with new $4.0 billion revolving credit facility replacing three historic facilities Cardinal Health announces long-term renewal of wholesaler distribution contract with Kroger New distribution center in Indianapolis set to open in 2027 featuring advanced robotics and automation, adding capacity and enabling operational flexibility Cardinal Health Board of Directors declared a regular quarterly dividend of $0.5158 per share, payable on October 15, 2026, to shareholders of record on October 1, 2026 Webcast

Cardinal Health will host a webcast today at 8:30 a.m. ET to discuss fourth quarter and full year results. To access the webcast and corresponding slide presentation, go to the Investor Relations page at ir.cardinalhealth.com. No access code is required. 

Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months.

About Cardinal Health

Cardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuclear pharmacies and manufacturing facilities; and a provider of performance and data solutions. Our company's customer-centric focus drives continuous improvement and leads to innovative solutions that improve people's lives every day. Learn more about Cardinal Health at cardinalhealth.com and in our Newsroom.

Contacts

Media: Erich Timmerman, [email protected] and 614.757.8231
Investors: David Frost, [email protected] and 614.757.7852

1GAAP refers to U.S. generally accepted accounting principles. This news release includes GAAP financial measures as well as non-GAAP financial measures, which are financial measures not calculated in accordance with GAAP. See "Use of Non-GAAP Measures" following the attached schedules for definitions of the non-GAAP financial measures presented in this news release and see the attached schedules for reconciliations of the differences between the non-GAAP financial measures and their most directly comparable GAAP financial measures.

2The company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. See "Use of Non-GAAP Measures" following the attached schedules for additional explanation. 

3Growth rates for fiscal year 2027 guidance based upon adjusted fiscal year 2026 results which exclude the fiscal year 2026 benefit from IEEPA tariff refund.

4Other includes the following three operating segments: Nuclear and Precision Health Solutions (NPHS), at-Home Solutions and OptiFreight Logistics, which are not significant enough individually to require reportable segment disclosure.

Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible on the Investor Relations page at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive email alerts when the company posts news releases, SEC filings and certain other information on its website.

Cautions Concerning Forward-Looking Statements

This release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and various accruals and estimates. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include our ability to manage uncertainties associated with the pricing of branded pharmaceuticals including those arising from proposed or final regulatory changes,  the risk that we may fail to achieve our strategic objectives, including the ongoing integration and operation of recently acquired entities and the continued execution of the GMPD Improvement Plan initiatives and ; risks and uncertainties related to tariffs, including the risk that we may not be able to offset increased costs; competitive pressures in Cardinal Health's various lines of business, including the risk that customers may reduce purchases made under their contracts with us or terminate or not renew their contracts, whether due to price increases or otherwise; risks associated with litigation matters, including Department of Justice investigations focused on potential violations of the Anti-Kickback Statute and False Claims Act; the risk that events outside of our control, such as weather or geopolitical events, including the recent conflict with Iran, may impact costs for our products or may cause supply delays or shortages or manufacturing delays that impact our cost and ability to fulfill customer demand; and the performance of our generics program, including the amount or rate of generic deflation and our ability to offset generic deflation and maintain other financial and strategic benefits through our generic sourcing venture or other components of our generics programs. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8K reports and exhibits to those reports. This release reflects management's views as of August 11, 2026. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement. Forward-looking statements are aspirational and not guarantees or promises that goals, targets or projections will be met, and no assurance can be given that any commitment, expectation, initiative or plan in this report can or will be achieved or completed. Cardinal Health provides definitions and reconciliations of non-GAAP financial measures and their most directly comparable GAAP financial measures at ir.cardinalhealth.com.

Schedule 1

Cardinal Health, Inc. and Subsidiaries

Consolidated Statements of Earnings (Unaudited)

Fourth  Quarter

Fiscal Year

(in millions, except per common share amounts)

2026

2025

% Change

2026

2025

% Change

Revenue

$     63,672

$     60,159

6 %

$    254,248

$    222,578

14 %

Cost of products sold

61,112

57,957

5 %

244,474

214,410

14 %

Gross margin

2,560

2,202

16 %

9,774

8,168

20 %

Operating expenses:

Distribution, selling, general and administrative expenses

1,625

1,484

10 %

6,132

5,382

14 %

Restructuring and employee severance

40

27

106

88

Amortization and other acquisition-related costs

121

133

469

464

Acquisition-related cash and share-based compensation costs

44

106

287

126

Impairments and (gain)/loss on disposal of assets, net 1

4

33

177

18

Litigation (recoveries)/charges, net

(3)

(9)

(10)

(185)

Operating earnings

729

428

70 %

2,613

2,275

15 %

Other (income)/expense, net

(26)

(30)

(31)

(41)

Interest expense, net

79

74

7 %

348

215

62 %

Impairment of equity interest in Outcomes

122

—

122

—

Earnings before income taxes

554

384

44 %

2,174

2,101

3 %

Provision for income taxes 2

154

141

9 %

469

532

(12) %

Net earnings

400

243

65 %

1,705

1,569

9 %

Less: Net (earnings)/loss attributable to noncontrolling interests

(2)

(4)

9

(8)

Net earnings attributable to Cardinal Health, Inc.

$       398

$        239

67 %

$      1,714

$      1,561

10 %

Earnings per common share attributable to Cardinal Health, Inc.:

Basic

$      1.70

$       1.01

68 %

$        7.27

$        6.48

12 %

Diluted

1.70

1.00

70 %

7.23

6.45

12 %

Weighted-average number of common shares outstanding:

Basic

234

239

236

241

Diluted

235

240

237

242

1 Impairments and (gain)/loss on disposals of assets, net includes pre-tax goodwill impairment charges of $184 million related to the Navista & ION reporting unit within the Pharma segment recorded in fiscal year ended 2026.

2 Provision for income taxes includes the tax effects relating to the cumulative goodwill impairment charges. For fiscal 2026, the net tax benefits related to the goodwill impairment charges was $23 million.

Schedule 2

Cardinal Health, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets (Unaudited)

(in millions)

June 30, 2026

June 30, 2025

Assets

Current assets:

Cash and equivalents

$         4,856

$         3,874

Trade receivables, net

13,815

13,242

Inventories, net

17,297

16,831

Prepaid expenses and other

2,764

2,414

Assets held for sale

21

12

Total current assets

38,753

36,373

Property and equipment, net

3,031

2,858

Goodwill and other intangibles, net

13,631

12,177

Other assets

1,884

1,714

Total assets

$        57,299

$        53,122

Liabilities and Shareholders' Deficit

Current liabilities:

Accounts payable

$        38,283

$        34,713

Current portion of long-term obligations and other short-term borrowings

1,882

550

Other accrued liabilities

3,739

3,634

Total current liabilities

43,904

38,897

Long-term obligations, less current portion

7,004

7,977

Deferred income taxes and other liabilities

9,115

8,882

Total shareholders' deficit

(2,724)

(2,634)

Total liabilities and shareholders' deficit

$        57,299

$        53,122

Schedule 3

Cardinal Health, Inc. and Subsidiaries

Consolidated Statements of Cash Flows (Unaudited)

Fourth  Quarter

Fiscal Year

(in millions)

2026

2025

2026

2025

Cash flows from operating activities:

Net earnings

$          400

$          243

$        1,705

1,569

Adjustments to reconcile net earnings to net cash provided by operating activities:

Depreciation and amortization

241

209

956

790

Impairments and (gain)/loss on sale of other investments, net

1

1

21

3

Impairment of equity interest in Outcomes

122

—

122

—

Impairments and (gain)/loss on disposal of assets, net

4

33

177

18

Share-based compensation

58

153

367

244

Provision for/(benefit from) deferred income taxes

91

243

91

243

Provision for bad debts

27

12

74

53

Change in operating assets and liabilities, net of effects from acquisitions and divestitures:

Increase in trade receivables

(193)

(466)

(408)

(833)

(Increase)/decrease in inventories

697

(607)

(488)

(1,816)

Increase in accounts payable

450

1,778

3,463

2,732

Repurchases of liability-classified Specialty Alliance Units

(18)

(19)

(45)

(19)

Other accrued liabilities and operating items, net

(188)

(60)

(861)

(587)

Net cash provided by operating activities

1,692

1,520

5,174

2,397

Cash flows from investing activities:

Acquisition of subsidiaries, net of cash acquired

(24)

(1,395)

(1,991)

(5,250)

Additions to property and equipment

(264)

(232)

(649)

(547)

Proceeds from disposal of property and equipment

—

—

31

3

Proceeds from investments

14

8

41

15

Proceeds from net investment hedge terminations

(6)

—

(13)

2

Proceeds from short-term investment in time deposit

—

—

—

200

Other investing items, net

(1)

(12)

(3)

(16)

Net cash used in investing activities

(281)

(1,631)

(2,584)

(5,593)

Cash flows from financing activities:

Proceeds from long-term obligations, net of issuance costs

(1)

800

990

3,669

Reduction of long-term obligations

(16)

(11)

(653)

(445)

Payments to noncontrolling interests, net

(3)

(5)

(11)

(12)

Net tax proceeds from share-based compensation

—

(1)

(79)

(13)

Dividends on common shares

(120)

(120)

(491)

(494)

Purchase of treasury shares

(350)

—

(1,358)

(765)

Net cash provided by/(used in) financing activities

(490)

663

(1,602)

1,940

Effect of exchange rates changes on cash and equivalents

(2)

(4)

(6)

(3)

Net increase/(decrease) in cash and equivalents

919

548

982

(1,259)

Cash and equivalents at beginning of period

3,937

3,326

3,874

5,133

Cash and equivalents at end of period

$        4,856

$        3,874

$        4,856

$        3,874

Schedule 4

Cardinal Health, Inc. and Subsidiaries

Segment Information (Unaudited)

Fourth Quarter

Pharmaceutical and Specialty Solutions

Global Medical Products and Distribution

Other

(in millions)

2026

2025

2026

2025

2026

2025

Revenue

Amount

$        58,848

$        55,372

$         3,128

$         3,199

$         1,721

$         1,609

Growth rate

6 %

— %

(2) %

3 %

7 %

37 %

Segment profit

Amount

$             645

$             535

$            150

$              70

$            183

$            160

Growth rate

21 %

11 %

N.M.

49 %

14 %

44 %

Segment profit margin

1.10 %

0.97 %

4.80 %

2.19 %

10.63 %

9.94 %

Fiscal Year

Pharmaceutical and Specialty Solutions

Global Medical Products and Distribution

Other

(in millions)

2026

2025

2026

2025

2026

2025

Revenue

Amount

$       234,833

$       204,644

$        12,719

$        12,636

$         6,792

$         5,382

Growth rate

15 %

(3) %

1 %

2 %

26 %

19 %

Segment profit

Amount

$           2,783

$           2,258

$             258

$             135

$           707

$           516

Growth rate

23 %

12 %

91 %

47 %

37 %

22 %

Segment profit margin

1.19 %

1.10 %

2.03 %

1.07 %

10.41 %

9.59 %

The sum of the components and certain computations may reflect rounding adjustments.

Schedule 5

Cardinal Health, Inc. and Subsidiaries

GAAP / Non-GAAP Reconciliation1 (Unaudited)

Net

(Earnings)/

Loss

Gross

Operating

Earnings

Provision

Attributable

Net

Diluted

Margin

SG&A2

Earnings

Before

for

to Non-

Earnings3

Effective

EPS 3

(in millions, except per common share amounts)

Gross

Growth

Growth

Operating

Growth

Income

Income

Controlling

Net

Growth

Tax

Diluted

Growth

Margin

Rate

SG&A 2

Rate

Earnings

Rate

Taxes

Taxes

Interests

Earnings3

Rate

Rate

EPS 3

Rate

Fourth Quarter 2026

GAAP

$ 2,560

16 %

$ 1,625

10 %

$    729

70 %

$   554

$    154

$       (2)

$    398

67 %

27.9 %

$ 1.70

70 %

Restructuring and employee severance

—

—

40

40

9

—

31

0.13

Amortization and other acquisition-related costs

—

—

121

121

28

—

93

0.40

Acquisition-related cash & share-based compensation costs

—

—

44

44

3

—

41

0.18

Impairments and (gain)/loss on disposal of assets, net

—

—

4

4

3

—

1

—

Litigation (recoveries)/charges, net

—

—

(3)

(3)

(3)

—

—

—

Impairment of equity interest in Outcomes 4

—

—

—

122

3

—

119

0.51

Non-GAAP

$ 2,560

16 %

$ 1,625

10 %

$    935

30 %

$   882

$    198

$       (2)

$    682

36 %

22.5 %

$ 2.91

40 %

Fourth Quarter 2025

GAAP

$ 2,202

17 %

$ 1,484

16 %

$    428

7 %

$    384

$    141

$       (4)

$    239

2 %

36.9 %

$ 1.00

4 %

Restructuring and employee severance

—

—

27

27

6

—

21

0.09

Amortization and other acquisition-related costs

—

—

133

133

23

2

112

0.46

Acquisition-related cash & share-based compensation costs

—

—

106

106

1

4

109

0.45

Impairments and (gain)/loss on disposal of assets, net

—

—

33

33

9

—

24

0.10

Litigation (recoveries)/charges, net

—

—

(9)

(9)

(2)

—

(7)

(0.03)

Non-GAAP

$  2,203

17 %

$ 1,484

16 %

$    719

19 %

$    676

$    178

$        3

$    501

11 %

26.3 %

$ 2.08

13 %

1 For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules.

2 Distribution, selling, general and administrative expenses.

3 Attributable to Cardinal Health, Inc.

4 For fiscal 2026, we recognized a pre-tax impairment charge of $122 million related to our equity method investment in Outcomes due to an observed reduction in the estimated fair value of the business, which is included in impairment of equity interest in Outcomes in the consolidated statements of earnings. The net tax benefit related to this charge was $3 million and is included in the annual effective tax rate.

The sum of the components and certain computations may reflect rounding adjustments.

We generally apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.

Schedule 5

Cardinal Health, Inc. and Subsidiaries

GAAP / Non-GAAP Reconciliation1 (Unaudited)

Net

(Earnings)/

Loss

Gross

Operating

Earnings

Provision

Attributable

Net

Diluted

Margin

SG&A2

Earnings

Before

for

to Non-

Earnings3

Effective

EPS 3

Gross

Growth

Growth

Operating

Growth

Income

Income

Controlling

Net

Growth

Tax

Diluted

Growth

(in millions, except per common share amounts)

Margin

Rate

SG&A 2

Rate

Earnings

Rate

Taxes

Taxes

Interests

Earnings3

Rate

Rate

EPS 3

Rate

Fiscal Year 2026

GAAP

$ 9,774

20 %

$ 6,132

14 %

$   2,613

15 %

$  2,174

$    469

$        9

$  1,714

10 %

21.6 %

$ 7.23

12 %

State opioid assessment related to prior fiscal years

—

17

(17)

(17)

(4)

—

(13)

(0.05)

Restructuring and employee severance

—

—

106

106

24

—

82

0.34

Amortization and other acquisition-related costs

—

—

469

469

120

—

349

1.47

Acquisition-related cash & share-based compensation costs

—

—

287

287

12

—

275

1.16

Impairments and (gain)/loss on disposal of assets, net 5

—

—

177

177

22

(23)

132

0.56

Litigation (recoveries)/charges, net

—

—

(10)

(10)

(19)

—

9

0.04

Impairment of equity interest in Outcomes 4

—

—

—

122

3

—

119

0.50

Non-GAAP

$ 9,774

20 %

$ 6,150

14 %

$   3,624

30 %

$  3,308

$    628

$      (13)

$  2,667

34 %

19.0 %

$ 11.26

37 %

Fiscal Year 2025

GAAP

$ 8,168

10 %

$ 5,382

8 %

$   2,275

83 %

$  2,101

$    532

$        (8)

$   1,561

83 %

25.3 %

$ 6.45

87 %

Restructuring and employee severance

—

—

88

88

21

—

67

0.28

Amortization and other acquisition-related costs

—

—

464

464

104

—

360

1.49

Acquisition-related cash & share-based compensation costs

—

—

126

126

1

—

125

0.51

Impairments and (gain)/loss on disposal of assets, net

—

—

18

18

5

—

13

0.05

Litigation (recoveries)/charges, net

—

—

(185)

(185)

(54)

—

(131)

(0.54)

Non-GAAP

$ 8,168

10 %

$ 5,382

8 %

$   2,786

15 %

$  2,612

$    609

$       (8)

$   1,995

7 %

23.3 %

$ 8.24

9 %

Fiscal Year 2024

GAAP

$ 7,414

8 %

$ 5,000

4 %

$   1,243

65 %

$  1,201

$    348

$       (1)

$    852

N.M.

28.9 %

$ 3.45

N.M.

Shareholder cooperation agreement costs

—

(1)

1

1

—

—

1

—

Restructuring and employee severance

—

—

175

175

41

—

134

0.54

Amortization and other acquisition-related costs

—

—

284

284

74

—

210

0.85

Impairments and (gain)/loss on disposal of assets, net 5

—

—

634

634

47

—

587

2.38

Litigation (recoveries)/charges, net

—

—

78

78

5

—

73

0.30

Non-GAAP

$ 7,414

8 %

$ 5,000

4 %

$   2,414

16 %

$  2,372

$    515

$       (1)

$   1,856

21 %

21.7 %

$ 7.53

29 %

1 For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules.

2 Distribution, selling, general and administrative expenses.

3 Attributable to Cardinal Health, Inc.

4 For fiscal 2026, we recognized a pre-tax impairment charge of $122 million related to our equity method investment in Outcomes due to an observed reduction in the estimated fair value of the business, which is included in impairment of equity interest in Outcomes in the consolidated statements of earnings. The net tax benefit related to this charge was $3 million and is included in the annual effective tax rate.

5 For fiscal 2026 and 2024, impairments and (gain)/loss on disposals of assets, net includes pre-tax goodwill impairment charges of $184 million related to the Navista & ION reporting unit within the Pharma segment and $675 million related to the GMPD segment, respectively. For fiscal 2026 and 2024 the net tax benefit related to these charges was $23 million and $58 million, respectively, and were included in the annual effective tax rates. The portion of the goodwill impairment charge within the Navista & ION reporting unit attributable to noncontrolling interests was $23 million for fiscal 2026.

The sum of the components and certain computations may reflect rounding adjustments.

We generally apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.

Schedule 6

Cardinal Health, Inc. and Subsidiaries

GAAP / Non-GAAP Reconciliation - GAAP Cash Flow to Non-GAAP Adjusted Free Cash Flow (Unaudited)

Fiscal Year

(in millions)

2026

2025

GAAP - Cash Flow Categories

Net cash provided by operating activities

$    5,174

$    2,397

Net cash used in investing activities

(2,584)

(5,593)

Net cash provided by/(used in) financing activities

(1,602)

1,940

Effect of exchange rates changes on cash and equivalents

(6)

(3)

Net increase/(decrease) in cash and equivalents

$       982

$   (1,259)

Non-GAAP Adjusted Free Cash Flow

Net cash provided by operating activities

$    5,174

$    2,397

Repurchases of liability-classified Specialty Alliance Units

45

19

Additions to property and equipment

(649)

(547)

Payments related to matters included in litigation (recoveries)/charges, net

401

619

Non-GAAP Adjusted Free Cash Flow

$    4,971

$    2,488

For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules.

Schedule 7

Cardinal Health, Inc. and Subsidiaries

Global Medical Product Distribution ("GMPD") and Consolidated

 International Emergency Economic Powers Act ("IEEPA") Tariff Refunds Reconciliation (Unaudited)

Global Medical Product Distribution

Fourth Quarter

Fiscal Year

(in millions)

2026

2025

Growth Rate

2026

2025

Growth Rate

Segment profit

$       150

$        70

N.M.

$       258

$       135

91 %

Less: IEEPA tariff refunds

100

—

100 %

100

—

100 %

Segment profit, excluding IEEPA tariff refunds

$         50

$        70

(29) %

$       158

$       135

17 %

Consolidated

Fourth Quarter

Fiscal Year

(in millions)

2026

2025

Growth Rate

2026

2025

Growth Rate

Net earnings 1

$       398

$       239

67 %

$    1,714

$    1,561

10 %

Less: IEEPA tariff refunds, net of tax

74

—

100 %

74

—

100 %

Net earnings, excluding IEEPA tariff refunds

$       324

$       239

36 %

$    1,640

$    1,561

5 %

Diluted EPS

$      1.70

$      1.00

70 %

$      7.23

$      6.45

12 %

Less: Diluted EPS, IEEPA tariff refunds, net of tax

0.31

—

100 %

0.31

—

100 %

Diluted EPS, excluding IEEPA tariff refunds

$      1.39

$      1.00

39 %

$      6.92

$      6.45

7 %

Consolidated

Fourth Quarter

Fiscal Year

(in millions)

2026

2025

Growth Rate

2026

2025

Growth Rate

Non-GAAP Net earnings 1

$       682

$       501

36 %

$     2,667

$    1,995

34 %

Less: IEEPA tariff refunds, net of tax

74

—

100 %

74

—

100 %

Non-GAAP Net earnings, excluding IEEPA tariff refunds

$       608

$       501

21 %

$     2,593

$    1,995

30 %

Non-GAAP Diluted EPS

$      2.91

$      2.08

40 %

$     11.26

$      8.24

37 %

Less: Non-GAAP Diluted EPS, IEEPA tariff refunds, net of tax

0.31

—

100 %

0.31

—

100 %

Non-GAAP Diluted EPS, excluding IEEPA tariff refunds

$      2.60

$      2.08

25 %

$     10.95

$      8.24

33 %

1 Attributable to Cardinal Health, Inc.

Schedule 8

Cardinal Health, Inc. and Subsidiaries

Distribution, Selling, General and Administrative ("SG&A") Expenses, excluding Acquisitions

Consolidated

Fourth Quarter

Fiscal Year

(in millions)

2026

2025

% Change

2026

2025

% Change

SG&A expenses

$     1,625

$     1,484

10 %

$     6,132

$     5,382

14 %

Less: Recent acquisitions1

198

157

26 %

767

254

N.M.

SG&A expenses, excluding recent acquisitions

$     1,427

$     1,327

8 %

$     5,365

$     5,128

5 %

1Recent acquisitions include Integrated Oncology Network (December 2024), GI Alliance (January 2025), Advanced Diabetes Supply Group (April 2025), Urology America (May 2025), and Solaris Health (November 2025).

Cardinal Health, Inc. and Subsidiaries

Use of Non-GAAP Measures

This earnings release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP").

In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated. 

Exclusions from Non-GAAP Financial Measures

Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors' assessment of the business for the reasons identified below:

LIFO charges and credits are excluded because the factors that drive last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies' financial results. We did not recognize any LIFO charges or credits during the periods presented. State opioid assessments related to prior fiscal years is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Income from state opioid assessments related to prior fiscal years represents reversals of accruals due to changes in estimates or when the underlying assessments were invalidated by a court or reimbursed by manufacturers.  Shareholder cooperation agreement costs includes costs such as legal, consulting, and other expenses incurred in relation to the agreement (the "Cooperation Agreement") entered into among Elliott Associates, L.P., Elliott International, L.P. (together, "Elliott"), and Cardinal Health. These include costs incurred to negotiate and finalize the Cooperation Agreement and costs incurred by the Business Review Committee of the Board of Directors, formed under this Cooperation Agreement, tasked with undertaking a comprehensive review of our strategy, portfolio, capital allocation framework, and operations. We have excluded these costs from our non-GAAP metrics because they do not occur in or reflect the ordinary course of our ongoing business operations and may obscure analysis of trends and financial performance. The Cooperation Agreement expired in the second quarter of fiscal 2025. Restructuring and employee severance costs are excluded because they are not part of the ongoing operations of our underlying business and include, but are not limited to, costs related to divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products, moving manufacturing of a product to another location, changes in production or business process outsourcing or insourcing, employee severance, and realigning operations.  Amortization and other acquisition-related costs, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets and amortization as a result of basis differences in equity method investments are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current, and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity's initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity, and size of acquisitions.  Acquisition-related cash and share-based compensation costs are incurred in connection with contingent cash payments or the issuance of share-based payment awards, which include service requirements, as a part of certain physician practice acquisitions. These costs include fair value adjustments for liability-classified awards. These costs are excluded because they are unrelated to the underlying operating results of our business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. In addition, the magnitude of these expenses is significantly impacted by the timing and size of the acquisitions of physician practices. Impairments and gain or loss on disposal of assets, net are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current, and forecasted financial results.  Litigation recoveries or charges, net are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business, and are inherently unpredictable in timing and amount.  Impairment of equity interest in Outcomes was incurred in connection with the observed reduction in the estimated fair value of the Outcomes business, of which we hold a 16 percent equity interest. We exclude this impairment from non-GAAP results as impairments of unconsolidated equity investments of this magnitude do not occur in the normal course of our ongoing business operations. This impairment is similar in nature to a gain or loss on the divestiture of a majority interest, which we also exclude from non-GAAP results, including the gain recognized on our initial divestiture of the Outcomes business in fiscal 2024. The exclusion of this impairment from non-GAAP financial measures facilitates comparison of our current financial results to our historical financial results. The tax effect for each of the items listed above is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax, and net impact of each item are presented with our GAAP to non-GAAP reconciliations.

Non-GAAP adjusted free cash flow: We provide this non-GAAP financial measure as a supplemental metric to assist readers in assessing the effects of items and events on our cash flow on a year-over-year basis and in comparing our performance to that of our peer group companies. In calculating this non-GAAP metric, certain items are excluded from net cash provided by operating activities because they relate to significant and unusual or non-recurring events and are inherently unpredictable in timing and amount. We believe adjusted free cash flow is important to management and useful to investors as a supplemental measure as it indicates the cash flow available for working capital needs, debt repayments, dividend payments, share repurchases, strategic acquisitions, or other strategic uses of cash. A reconciliation of our GAAP financial results to Non-GAAP adjusted free cash flow is provided in Schedule 6 of the financial statement tables included with this release.

Forward Looking Non-GAAP Measures

In this document, the Company presents certain forward-looking non-GAAP metrics. The Company does not provide outlook on a GAAP basis because the items that the Company excludes from GAAP to calculate the comparable non-GAAP measure can be dependent on future events that are less capable of being controlled or reliably predicted by management and are not part of the Company's routine operating activities. Additionally, management does not forecast many of the excluded items for internal use and therefore cannot create or rely on outlook done on a GAAP basis.
 

The occurrence, timing and amount of any of the items excluded from GAAP to calculate non-GAAP could significantly impact the Company's fiscal 2026 GAAP results. Over the past five fiscal years, the excluded items have impacted the Company's EPS from $1.79 to $8.44, which includes a $6.97 change related to the goodwill impairment we recognized in fiscal 2022.

Definitions

Growth rate calculation: growth rates in this report are determined by dividing the difference between current-period results and prior-period results by prior-period results.

Interest and Other, net: other (income)/expense, net plus interest expense, net.

Segment Profit: segment revenue minus (segment cost of products sold and segment distribution, selling, general and administrative expenses).

Segment Profit margin: segment profit divided by segment revenue.

Non-GAAP gross margin: gross margin, excluding LIFO charges/(credits).

Non-GAAP distribution, selling, general and administrative expenses or Non-GAAP SG&A: distribution, selling, general and administrative expenses, excluding state opioid assessment related to prior fiscal years and shareholder cooperation agreement costs.

Non-GAAP operating earnings: operating earnings excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) acquisition-related cash and share-based compensation costs, (7) impairments and (gain)/loss on disposal of assets, net, and (8) litigation (recoveries)/charges, net.

Non-GAAP earnings before income taxes: earnings before income taxes excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) acquisition-related cash and share-based compensation costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net, and (9) impairment of equity interest in Outcomes.

Non-GAAP net earnings attributable to non-controlling interests: net earnings attributable to non-controlling interests excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) acquisition-related cash and share-based compensation costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net, and (9) impairment of equity interest in Outcomes, each net of tax.

Non-GAAP net earnings attributable to Cardinal Health, Inc.: net earnings attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) acquisition-related cash and share-based compensation costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net, and (9) impairment of equity interest in Outcomes, each net of tax.

Non-GAAP effective tax rate: provision for income taxes adjusted for the tax impacts of (1) LIFO charges/(credits), (2) state opioid assessment related to prior fiscal years, (3) shareholder cooperation agreement costs, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) acquisition-related cash and share-based compensation costs, (7) impairments and (gain)/loss on disposal of assets, net, (8) litigation (recoveries)/charges, net, and (9) impairment of equity interest in Outcomes, divided by (earnings before income taxes adjusted for the items above).

Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding.

Non-GAAP adjusted free cash flow: net cash provided by operating activities plus repurchases of liability-classified Specialty Alliance Units, less payments related to additions to property and equipment, excluding settlement payments and receipts related to matters included in litigation (recoveries)/charges, net, as defined above, or other significant and unusual or non-recurring cash payments or receipts.

SOURCE Cardinal Health, Inc.

With U.S. stock futures trading mixed this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:

Wall Street expects Super Micro Computer Inc. (NASDAQ:SMCI) to post quarterly earnings of 62 cents per share on revenue of $12.33 billion after the closing bell, according to data from Benzinga Pro. Super Micro Computer shares gained 1.1% to $31.81 in after-hours trading. Upwork Inc. (NASDAQ:UPWK) posted better-than-expected earnings for the second quarter. Upwork reported quarterly earnings of 41 cents per share, which beat the consensus estimate of 34 cents, according to Benzinga Pro data. Quarterly revenue came in at $191.66 million, which beat the Street estimate of $189.96 million, but was down from $194.94 million in the same period last year. Upwork shares dipped 20.3% to $7.84 in the after-hours trading session. Analysts are expecting Cardinal Health, Inc (NYSE:CAH) to post quarterly earnings of $2.42 per share on revenue of $65.03 billion. The company will release earnings before the markets open. Cardinal Health shares gained 0.5% to $238.30 in after-hours trading. Check out our premarket coverage here

Babcock & Wilcox Enterprises Inc. (NYSE:BW) reported better-than-expected second-quarter results and increased its full-year 2026 adjusted EBITDA target. Babcock & Wilcox shares jumped 41.6% to $12.58 in the after-hours trading session. Analysts expect Aramark (NYSE:ARMK) to post quarterly earnings of 48 cents per share on revenue of $4.94 billion before the opening bell. Aramark shares rose 1.7% to $56.63 in after-hours trading. Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.